FTHFaeth TherapeuticsSigning up patients
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Endometrial Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.6
2 insiders sold shares within a month
Since Jun 1, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 40 (planned)
- Started
- Dec 12, 2024
- Main results expected
- Sep 2028
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: Up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.6, since 2026-06-01, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06463028 · record last updated 2025-12-24 · checked 2026-11-09 15:36 UTC